Helen M. Colhoun

40.6k total citations · 13 hit papers
278 papers, 19.3k citations indexed

About

Helen M. Colhoun is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Helen M. Colhoun has authored 278 papers receiving a total of 19.3k indexed citations (citations by other indexed papers that have themselves been cited), including 149 papers in Endocrinology, Diabetes and Metabolism, 97 papers in Surgery and 52 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Helen M. Colhoun's work include Diabetes Treatment and Management (85 papers), Lipoproteins and Cardiovascular Health (64 papers) and Diabetes Management and Research (48 papers). Helen M. Colhoun is often cited by papers focused on Diabetes Treatment and Management (85 papers), Lipoproteins and Cardiovascular Health (64 papers) and Diabetes Management and Research (48 papers). Helen M. Colhoun collaborates with scholars based in United Kingdom, United States and Netherlands. Helen M. Colhoun's co-authors include Shona Livingstone, John Fuller, Paul McKeigue, G. A. Hitman, Paul N. Durrington, D. J. Betteridge, H. A. W. Neil, Valentine Charlton-Menys, George Davey Smith and Margaret J. Thomason and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Helen M. Colhoun

273 papers receiving 18.7k citations

Hit Papers

Primary prevention of car... 2003 2026 2010 2018 2004 2023 2015 2003 2012 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
    2004 2.7k citations Helen M. Colhoun et al. profile →
  2. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
    2023 1.3k citations A. Michael Lincoff, Kirstine Brown‐Frandsen et al. profile →
  3. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials
    2015 1.0k citations Helen M. Colhoun et al. profile →
  4. Problems of reporting genetic associations with complex outcomes
    2003 876 citations Helen M. Colhoun, Paul McKeigue et al. profile →
  5. Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins
    2012 577 citations Helen M. Colhoun et al. profile →
  6. Estimated Life Expectancy in a Scottish Cohort With Type 1 Diabetes, 2008-2010
    2015 418 citations Helen C. Looker, Robert S. Lindsay et al. profile →
  7. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
    2018 365 citations Helen M. Colhoun et al. profile →
  8. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
    2015 316 citations Helen M. Colhoun et al. profile →
  9. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study
    2015 291 citations Helen M. Colhoun et al. profile →
  10. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
    2024 123 citations Donna H. Ryan, Ildiko Lingvay et al. profile →
  11. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
    2024 102 citations Helen M. Colhoun, Ildiko Lingvay et al. profile →
  12. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
    2024 100 citations John Deanfield, Subodh Verma et al. profile →
  13. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials
    2024 80 citations Naveed Sattar, Peter Rossing et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Helen M. Colhoun 8.8k 8.0k 4.2k 2.4k 2.3k 278 19.3k
H. A. W. Neil 10.3k 1.2× 6.5k 0.8× 3.3k 0.8× 1.6k 0.7× 2.6k 1.1× 113 17.4k
Mark J. Caulfield 6.2k 0.7× 6.0k 0.8× 8.2k 2.0× 1.8k 0.8× 2.1k 0.9× 170 17.2k
Michael H. Davidson 8.4k 1.0× 12.9k 1.6× 4.5k 1.1× 3.1k 1.3× 2.9k 1.2× 420 23.1k
James M. McKenney 7.6k 0.9× 10.2k 1.3× 5.0k 1.2× 3.3k 1.4× 1.6k 0.7× 155 21.1k
Winfried März 5.6k 0.6× 7.2k 0.9× 4.8k 1.1× 1.0k 0.4× 4.0k 1.7× 662 24.3k
Kausik K. Ray 10.2k 1.2× 14.7k 1.8× 6.7k 1.6× 3.4k 1.4× 5.0k 2.1× 466 26.5k
Jonathan Emberson 4.1k 0.5× 7.6k 1.0× 6.3k 1.5× 2.5k 1.0× 1.3k 0.5× 134 20.8k
Chris J. Packard 7.4k 0.8× 8.1k 1.0× 4.8k 1.1× 1.5k 0.6× 2.5k 1.1× 209 19.1k
Donald B. Hunninghake 9.4k 1.1× 11.3k 1.4× 7.5k 1.8× 3.5k 1.4× 2.0k 0.9× 167 26.4k
Peter P. Tóth 5.4k 0.6× 8.4k 1.0× 3.9k 0.9× 1.8k 0.8× 2.2k 0.9× 529 16.7k

Countries citing papers authored by Helen M. Colhoun

Since Specialization
Citations

This map shows the geographic impact of Helen M. Colhoun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helen M. Colhoun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helen M. Colhoun more than expected).

Fields of papers citing papers by Helen M. Colhoun

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helen M. Colhoun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helen M. Colhoun. The network helps show where Helen M. Colhoun may publish in the future.

Co-authorship network of co-authors of Helen M. Colhoun

This figure shows the co-authorship network connecting the top 25 collaborators of Helen M. Colhoun. A scholar is included among the top collaborators of Helen M. Colhoun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helen M. Colhoun. Helen M. Colhoun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
McGurnaghan, Stuart J., Luke A. K. Blackbourn, Joseph Mellor, et al.. (2024). Ongoing burden and recent trends in severe hospitalised hypoglycaemia events in people with type 1 and type 2 diabetes in Scotland: A nationwide cohort study 2016–2022. Diabetes Research and Clinical Practice. 210. 111642–111642. 4 indexed citations
2.
Fu, Edouard L., Stuart J. McGurnaghan, Bryan R. Conway, et al.. (2024). Stopping Versus Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation Study. American Journal of Kidney Diseases. 85(2). 196–204.e1. 2 indexed citations
3.
Verma, Subodh, Helen M. Colhoun, Dror Dicker, et al.. (2024). Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT). Journal of the American College of Cardiology. 84(17). 1678–1682. 11 indexed citations
4.
Scirica, Benjamin M., A. Michael Lincoff, Ildiko Lingvay, et al.. (2024). The Effect of Semaglutide on Mortality and COVID-19–Related Deaths. Journal of the American College of Cardiology. 84(17). 1632–1642. 22 indexed citations
5.
Brown‐Frandsen, Kirstine, Helen M. Colhoun, John Deanfield, et al.. (2024). Semaglutide and cardiovascular outcomes in patients with overweight or obesity who do not have diabetes. Obesity Research & Clinical Practice. 18(5). S36–S36. 1 indexed citations
6.
Mellor, Joseph, Dmitry Kuznetsov, Simon Heller, et al.. (2024). Estimating risk of consequences following hypoglycaemia exposure using the Hypo-RESOLVE cohort: a secondary analysis of pooled data from insulin clinical trials. Diabetologia. 67(10). 2210–2224. 2 indexed citations
7.
Latres, Esther, Carla J. Greenbaum, Colin Dayan, et al.. (2024). Evidence for C-Peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes. Diabetes. 73(6). 823–833. 15 indexed citations
8.
9.
Aizawa, Kunihiko, Francesco Casanova, Phillip E. Gates, et al.. (2021). Reservoir-Excess Pressure Parameters Independently Predict Cardiovascular Events in Individuals With Type 2 Diabetes. Hypertension. 78(1). 40–50. 5 indexed citations
10.
Höhn, Andreas, Anita Jeyam, Thomas M. Caparrotta, et al.. (2021). The association of polypharmacy and high-risk drug classes with adverse health outcomes in the Scottish population with type 1 diabetes. Diabetologia. 64(6). 1309–1319. 5 indexed citations
11.
O’Reilly, Joseph, Anita Jeyam, Thomas M. Caparrotta, et al.. (2021). Rising Rates and Widening Socioeconomic Disparities in Diabetic Ketoacidosis in Type 1 Diabetes in Scotland: A Nationwide Retrospective Cohort Observational Study. Diabetes Care. 44(9). 2010–2017. 16 indexed citations
12.
Marcovecchio, M. Loredana, Marco Colombo, R. Neil Dalton, et al.. (2020). Biomarkers associated with early stages of kidney disease in adolescents with type 1 diabetes. Pediatric Diabetes. 21(7). 1322–1332. 10 indexed citations
13.
14.
15.
Read, Stephanie H., Merel van Diepen, Helen M. Colhoun, et al.. (2018). Performance of Cardiovascular Disease Risk Scores in People Diagnosed With Type 2 Diabetes: External Validation Using Data From the National Scottish Diabetes Register. Diabetes Care. 41(9). 2010–2018. 41 indexed citations
16.
Weir‐McCall, Jonathan, Faisel Khan, Deirdre Cassidy, et al.. (2017). Effects of inaccuracies in arterial path length measurement on differences in MRI and tonometry measured pulse wave velocity. BMC Cardiovascular Disorders. 17(1). 118–118. 17 indexed citations
17.
Casanova, Francesco, Damilola D. Adingupu, F. Dennette Adams, et al.. (2017). The impact of cardiovascular co-morbidities and duration of diabetes on the association between microvascular function and glycaemic control. Cardiovascular Diabetology. 16(1). 114–114. 54 indexed citations
18.
Chaturvedi, Nish, Ian Ford, Irene Hramiak, et al.. (2016). Metformin in type 1 diabetes: methods and baseline characteristics of the REMOVAL trial. UCL Discovery (University College London). 1 indexed citations
19.
Colhoun, Helen M., et al.. (2016). The REMOVAL trial (Reducing with Metformin Vascular Adverse Lesions) in Type 1 diabetes: methods and baseline characteristics. UCL Discovery (University College London). 1 indexed citations
20.
MacAllister, RJ, et al.. (2000). Impaired nitric oxide response in resistance vessels in human type 1 diabetes in vivo. UCL Discovery (University College London). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by H. A. W. Neil Breakdown of academic impact, for papers by Mark J. Caulfield Breakdown of academic impact, for papers by Michael H. Davidson Breakdown of academic impact, for papers by James M. McKenney Breakdown of academic impact, for papers by Winfried März Breakdown of academic impact, for papers by Kausik K. Ray Breakdown of academic impact, for papers by Jonathan Emberson Breakdown of academic impact, for papers by Chris J. Packard Breakdown of academic impact, for papers by Donald B. Hunninghake Breakdown of academic impact, for papers by Peter P. Tóth
Rankless by CCL
2026